{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:28:38Z","timestamp":1791260918951,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:sec id=\"ab-dbr230010-4\"><jats:title>Importance<\/jats:title><jats:p>Vitiligo has substantial psychosocial consequences. Yet its burden is poorly established.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230010-5\"><jats:title>Objective<\/jats:title><jats:p>To estimate incidence and prevalence of diagnosed vitiligo across age, sex, and racial and ethnic subgroups in the US.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230010-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This analysis comprising a cohort study and cross-sectional study included electronic health records for health care\u2013seeking children, adolescents, and adults across 4 US census regions. Data for the incidence analysis were obtained from January 1, 2015, through December 31, 2019, and data for the prevalence analysis were obtained from January 1 through December 31, 2019. Data were analyzed from December 13, 2022, to June 8, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230010-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The main outcomes were incidence (per 100\u202f000 person-years [PY]) and prevalence of diagnosed vitiligo overall and by age, race and ethnicity, and sex.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230010-8\"><jats:title>Results<\/jats:title><jats:p>A total of 2\u202f980\u202f778 patients with vitiligo were included in the incidence analysis (mean [SD] age, 41.5 [24.0] years; 57.0% female; 1.4% Asian American; 12.9% Black; 1.5% Hispanic\/Latino; 77.3% White; 6.9% other or multiracial) and 1\u202f057\u202f534 in the prevalence analysis (mean [SD] age, 43.4 [24.7] years; 57.5% female; 1.7% Asian American, 14.7% Black, 1.4% Hispanic\/Latino; 75.7% White; 6.6% other or multiracial). Age- and sex-adjusted overall incidence rate (IR) of diagnosed vitiligo was 22.6 per 100\u202f000 PY (95% CI, 21.5-23.8 per 100\u202f000 PY), and prevalence was 0.16% (95% CI, 0.15%-0.17%). Sex-adjusted IR was highest among patients aged 60 to 69 years (25.3 per 100\u202f000 PY; 95% CI, 22.2-28.6 per 100\u202f000 PY), and prevalence was highest among patients aged 70 years or older (0.21%; 95% CI, 0.19%-0.23%). The highest age-adjusted IR was observed among Asian American patients (41.2 per 100\u202f000 PY; 95% CI, 28.2-58.2 per 100\u202f000 PY), followed by Hispanic\/Latino patients (37.3 per 100\u202f000 PY; 95% CI, 25.7-52.4 per 100\u202f000 PY), patients reporting other or multiple races (31.1 per 100\u202f000 PY; 95% CI, 25.9-37.1 per 100\u202f000 PY), Black patients (29.6 per 100\u202f000 PY; 95% CI, 26.0-33.6 per 100\u202f000 PY), and White patients (18.7 per 100\u202f000 PY; 95% CI, 17.5-20.0 per 100\u202f000 PY). The highest age-adjusted prevalence was observed among Hispanic\/Latino patients (0.29%; 95% CI, 0.20%-0.39%), followed by Asian American patients (0.27%; 95% CI, 0.19%-0.35%), patients reporting other or multiple races (0.24%; 95% CI, 0.20%-0.28%), Black patients (0.22%; 95% CI, 0.19%-0.24%), and White patients (0.13%; 95% CI, 0.12%-0.14%).<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230010-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cross-sectional study found that vitiligo diagnosis was more common in older patients, Hispanic\/Latino patients, and Asian American patients.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2162","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T15:15:42Z","timestamp":1689779742000},"page":"986","source":"Crossref","is-referenced-by-count":41,"title":["Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US"],"prefix":"10.1001","volume":"159","author":[{"given":"Nicole","family":"Mastacouris","sequence":"first","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Strunk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"dbr230010r1","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo.","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"dbr230010r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo.","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"dbr230010r3","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.v36.10","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"dbr230010r4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review.","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"dbr230010r5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","article-title":"Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population.","volume":"82","author":"Hadi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"dbr230010r6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","article-title":"Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study.","volume":"74","author":"Gill","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dbr230010r7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/all.2017.72.issue-5","article-title":"Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses\u2019 Health Study 2.","volume":"72","author":"Drucker","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"dbr230010r8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States.","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"dbr230010r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.027","author":"Ahmed","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dbr230010r10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jaad.2016.12.043","article-title":"The burden of skin disease in the United States.","volume":"76","author":"Lim","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr230010r11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology.","volume":"55","author":"Bickers","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"212","key":"dbr230010r12","first-page":"i","article-title":"Skin conditions and related need for medical care among persons 1-74 years: United States, 1971-1974.","author":"Johnson","year":"1978","journal-title":"Vital Health Stat 11"},{"issue":"7","key":"dbr230010r15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d Research Program.","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med"},{"key":"dbr230010r13","unstructured":"IBM Watson Health. The IBM Explorys Platform: liberate your healthcare data. Accessed December 22, 2022. https:\/\/www.ibm.com\/downloads\/cas\/4P0QB9JN"},{"key":"dbr230010r14","unstructured":"US Census Bureau. 2019 American Community Survey 1-year estimates detailed tables: sex by age (B01001). Accessed March 25, 2022. https:\/\/data.census.gov\/cedsci\/table?q=american%20community%20survey%20b01001&tid=ACSDT1Y2019.B01001."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2807395\/jamadermatology_mastacouris_2023_br_230010_1695075753.00581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:16:16Z","timestamp":1695222976000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2807395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2162","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}